dual aurora/ALK kinase inhibitors (Sareum)

N/A

Report date: 2025/03/19 20:00:56
NME

Base Information

Drug Namedual aurora/ALK kinase inhibitors (Sareum)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase Aurora inhibitorsAnaplastic lymphoma kinase inhibitors
TargetsAnaplastic lymphoma kinaseSerine/threonine-protein kinase Aurora
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSareum Holdings plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSareum Holdings plc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A